Keytruda takes on rare skin sarcomas in new trial
NCT ID NCT07007273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 17 adults with advanced cutaneous sarcomas (excluding angiosarcoma). Participants receive an IV infusion every 3 weeks. The main goal is to see if tumors shrink, with additional tracking of survival and progression. It is an early study to check if the drug works for this rare cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced cutaneous sarcomas that are hard to treat.
- What could go wrong
- This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects like immune reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States